Corixa Bexxar patents ruled invalid
Executive Summary
San Diego federal court grants Idec motion for summary judgment Oct. 10, declaring four Bexxar (tositumomab) patents (Nos. 5,595,721; 6,015,542; 6,090,365; 6,287,537) invalid based on inequitable conduct of the inventors in not disclosing highly material prior art before the Patent & Trademark Office. "The manner in which [the work] was brought before the PTO cannot be described as anything short of misleading and inaccurate," the ruling states. Corixa and Bexxar marketing partner GSK originally sought to enjoin Idec from infringing the '721, '542, and '365 patents (1"The Pink Sheet" Sept. 24, 2001, p. 29). Corixa plans to appeal the ruling...
You may also be interested in...
Corixa Bexxar ruling reversed
Biogen Idec motion for summary judgment in Bexxar (tositumomab) patent litigation denied by San Diego federal court Jan. 22, reversing previous order. The court granted Biogen's motion on Oct. 14, 2003, holding that Corixa's Bexxar patents (nos. 5,595,721; 6,015,542; 6,090,365; and 6,287,537) were unenforceable (1"The Pink Sheet" Oct. 20, 2003, In Brief). Litigation in San Diego court will continue...
Idec, GSK, Corixa Discussing Licensing Of Radioimmunotherapy Patents
Idec is considering licensing patents from Corixa that may cover its radioimmunotherapy Zevalin.
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.